Evidence map›Paper›PMID 28545465›Full record

ArticleBMC cancer2017

An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma.

Yi Xu, Yanyue Tong, Jianyong Zhu, Zhangming Lei, Lijun Wan, Xiuwen Zhu, Feng Ye, Liping Xie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Computational and structural biotechnology journal · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yi XuDepartment of Urology, Quzhou Hospital, Zhejiang University, Quzhou City, 324000, China.
Yanyue TongDepartment of Urology, Quzhou Hospital, Zhejiang University, Quzhou City, 324000, China.
Jianyong ZhuDepartment of Urology, Quzhou Hospital, Zhejiang University, Quzhou City, 324000, China.
Zhangming LeiDepartment of Urology, Quzhou Hospital, Zhejiang University, Quzhou City, 324000, China.
Lijun WanDepartment of Urology, Quzhou Hospital, Zhejiang University, Quzhou City, 324000, China.
Xiuwen ZhuDepartment of Urology, Quzhou Hospital, Zhejiang University, Quzhou City, 324000, China.
Feng YeDepartment of Urology, Quzhou Hospital, Zhejiang University, Quzhou City, 324000, China.
Liping XieDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou City, 310003, China. xielp@zju.edu.cn.
Zhejiang University · CNFirst Affiliated Hospital Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNearly 30% of clear cell renal cell carcinoma (ccRCC) patients present with metastasis at the time of diagnosis, and the prognosis for these patients is poor. Therefore, novel potential prognostic biomarkers and therapeutic targets for ccRCC could be helpful. Emerging evidence indicates that lncRNAs play important roles in cancer tumorigenesis and could be used as potential biomarkers or therapeutic targets. PANDAR (promoter of CDKN1A antisense DNA damage activated RNA) is a relatively novel lncRNA that plays an important role in the development of multiple cancers. However, the clinical significance and molecular mechanism of PANDAR in ccRCC are still elusive. In the present study, we attempted to elucidate the role of PANDAR in ccRCC.

methodsThe relative expression level of lncRNA PANDAR was quantified by real-time qPCR in 62 paired ccRCC tissues and in renal cancer cell lines, and its association with overall survival was assessed by statistical analysis. The biological functions of lncRNA PANDAR on ccRCC cells were determined both in vitro and in vivo.

resultsPANDAR expression was significantly upregulated in tumor tissues and cell lines compared with normal counterparts. Moreover, PANDAR served as an independent predictor of overall survival, and increased PANDAR expression was positively correlated with an advanced TNM stage. Further experiments demonstrated that PANDAR silencing can significantly inhibit cell proliferation and invasion, induce cell cycle arrest in the G1 phase and significantly promote apoptosis in 7860 and Caki-1 cell lines. In addition, in vivo experiments confirmed that downregulation of PANDAR inhibited the tumorigenic ability of 7860 cells in nude mice. Silencing of PANDAR also inhibited the expression of Bcl-2 and Mcl-1 and upregulated the expression of Bax in vivo.

conclusionsOur results suggest that PANDAR is involved in ccRCC progression and may serve as a potential prognostic biomarker and therapeutic target.

Indexed as

Gene Expression Regulation, NeoplasticSignal TransductionAnimalsApoptosisCarcinoma, Renal CellCell Line, TumorCell ProliferationFemaleHumansKidney NeoplasmsMaleMiceMice, NudeMiddle AgedNeoplasm InvasivenessPrognosislong non-coding RNA PANDAR, humanProto-Oncogene Proteins c-bcl-2RNA, Long NoncodingApoptosisccRCClncRNAPANDARPI3K/Akt/mTOR

Identifiers

PMID28545465
PMCPMC5445460
OpenAlexW2618884748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.